RxDoctor Payments Data

Cynthia Glenn-Birkhead

Family · Whitesville, KYNPI 1598720625

Payments from drug & device makers

$1,384in general payments, 2019–2025

Across 37 payments — averaging $37.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165
  • Madrigal Pharmaceuticals$150
  • Amgen$146
  • AstraZeneca$117
  • Abiomed$108
  • Medtronic$108
  • plus $590 from 13 others

What the payments were for

  • Food & beverage$1,384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$48,501
Medicare patients
136
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate16$21,905
OzempicSemaglutide17$17,654
FarxigaDapagliflozin Propanediol18$15,740
TrulicityDulaglutide15$12,736
JardianceEmpagliflozin13$11,665
EliquisApixaban13$10,957
JanumetSitagliptin Phos/Metformin Hcl19$9,949
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,744
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$2,775
Prasugrel Hcl16$2,428
Atorvastatin Calcium217$1,553
Fluoxetine Hcl169$1,510
Rosuvastatin Calcium124$1,384
Levothyroxine Sodium170$1,233
Losartan Potassium144$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$117$15,74018 claims
Lilly USA, LLCTrulicity$46$12,73615 claims
Boehringer IngelheimJardiance$59$11,66513 claims
PfizerEliquis$38$10,95713 claims
AbbVieSynthroid$165$60623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Whitesville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →